



## REINSURANCE **HOT NEWS**

April 1, 2026

AHCCCS is pleased to announce the addition 6 of the following drugs to the High-Cost Specialty Drug Reinsurance (BIO) effective:

**Effective January 1, 2026:**

**CORTROPHIN** - (Corticotropin) - Indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age.

**ONPATTRO** - (Patirisiran) - Indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

**ITVISMMA**-(Onasemnogene Apeparvovec-brve)- Treatment of adult and pediatric patients  $\geq 2$  years of age with spinal muscular atrophy with confirmed mutation in SMN1 gene.

**Effective March 1, 2026:**

**VYKAT XR-** (Diazoxide Choline)- Indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome.

**Effective October 1,2026:**

**LAMZEDE-** (Velmanase Alfa-tycv)- Indicated for the treatment of noncentral nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.

**MYALEPT-** (Metreleptin) - Indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

*Reminder from the Reinsurance Manual (Page 20)*

*"For multiple reinsurance drugs to treat the same medical condition, please refer to the AHCCCS Fee For Service prior authorization criteria to determine if the criterion supports the use of multiple medications given/administered at the same time to an individual. When the prior authorization criterion is not supportive of the use of multiple drugs to treat the same condition, the reinsurance program will not reimburse multiple medications. For additional questions, please check with the Medical Management staff assigned to the MCO. "*

Here is the Link to the Updated High-Cost Specialty Drug List:  
<https://www.azahcccs.gov/PlansProviders/Downloads/Reinsurance/BiologicandHighCostSpecialtyDrugList.xlsx>